A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) (NCT07044297)
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection as well as or better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham-UAB 1917 Research Clinic ( Site 0006) — Birmingham, Alabama
Age range: 16 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (81 Sites)
Showing the first 25 of 81 sites.
- University of Alabama at Birmingham-UAB 1917 Research Clinic ( Site 0006) — Birmingham, Alabama
- USA Health University Hospitals ( Site 0020) — Mobile, Alabama
- UCLA Center for Clinical AIDS Research and Education ( Site 0004) — Los Angeles, California
- Bridge HIV - San Francisco Department of Public Health ( Site 0001) — San Francisco, California
- Whitman-Walker Institute ( Site 0016) — Washington D.C., District of Columbia
- University of Miami RAPID Research ( Site 0003) — Miami, Florida
- Orlando Immunology Center ( Site 0021) — Orlando, Florida
- Hope Clinic of the Emory Vaccine Center ( Site 0009) — Decatur, Georgia
- University of Illinois Chicago ( Site 0027) — Chicago, Illinois
- University Medical Center New Orleans ( Site 0024) — New Orleans, Louisiana
- Open Arms Healthcare Center ( Site 0025) — Jackson, Mississippi
- Rutgers New Jersey Medical School ( Site 0010) — Newark, New Jersey
- Montefiore Medical Center ( Site 0017) — The Bronx, New York
- NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill ( Site 0008) — Chapel Hill, North Carolina
- Regional Center for Infectious Diseases ( Site 0018) — Greensboro, North Carolina
- Philadelphia Fight Community Health Centers ( Site 0011) — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center-Division of Infectious Diseases ( Site 0022) — Pittsburgh, Pennsylvania
- Prisma Health Richland Hospital-Clinical Research Unit ( Site 0007) — Columbia, South Carolina
- St. Jude Children's Research Hospital ( Site 0026) — Memphis, Tennessee
- Meharry Medical College ( Site 0013) — Nashville, Tennessee
- Central Texas Clinical Research ( Site 0014) — Austin, Texas
- Saint Hope Foundation, Inc. ( Site 0015) — Bellaire, Texas
- Fred Hutchinson Cancer Center - The Seattle HIV Vaccine Trials Unit ( Site 0002) — Seattle, Washington
- Centro de Estudios Infectológicos S.A. ( Site 0357) — CABA, Buenos Aires
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada ( Site 0352) — CABA, Buenos Aires
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Human Immunodeficiency Virus (HIV)
- The Effects of Chiropractic Care on Inflammation and Quality of Life in People Living With HIV — Marietta, Georgia
- C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States — Atlanta, Georgia
- Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care — New York, New York
- Persuasive Health Communication Intervention for HIV/HCV — New York, New York
- Reducing Systemic Inflammation in People on Antiretroviral Therapy — Montreal, Quebec
Explore by condition: All Human Immunodeficiency Virus (HIV) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.